{"title":"c反应蛋白-白蛋白淋巴细胞指数对纳武单抗治疗的复发性(o)转移性头颈部鳞状细胞癌患者的预后价值。","authors":"Fumihiko Sato, Takeharu Ono, Akira Hiraki, Tsunehiro Oka, Toshiyuki Mitsuhashi, Masayasu Naito, Mioko Fukahori, Shintaro Sueyoshi, Itaru Mizobe, Masahiro Seki, Kiminobu Sato, Toshihiko Kawaguchi, Hisaichiro Tanaka, Takashi Kurita, Shun-Ichi Chitose, Hirohito Umeno","doi":"10.21873/anticanres.17757","DOIUrl":null,"url":null,"abstract":"<p><strong>Background/aim: </strong>Systemic inflammation, immunity, and nutrition-based prognostic indices (SIINBPIs) have been associated with cancer prognosis. This study evaluated their prognostic relevance in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) treated with nivolumab.</p><p><strong>Patients and methods: </strong>We retrospectively analyzed 103 R/M HNSCC patients who received nivolumab. Pretreatment blood tests were used to calculate SIINBPIs including the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), lymphocyte-to-monocyte ratio (LMR), high-sensitivity modified Glasgow Prognostic Score (HS-mGPS), and the C-reactive protein-albumin-lymphocyte (CALLY) index.</p><p><strong>Results: </strong>The CALLY index and performance status were identified as independent prognostic factors for overall survival (OS). Patients with a high CALLY index had better performance status and were more likely to receive subsequent chemotherapy. The CALLY index showed superior prognostic performance over other SIINBPIs.</p><p><strong>Conclusion: </strong>The CALLY index may serve as a useful and independent prognostic biomarker for R/M HNSCC patients undergoing nivolumab therapy, reflecting systemic status and predicting treatment outcomes.</p>","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"45 9","pages":"3993-4004"},"PeriodicalIF":1.7000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Prognostic Value of the C-Reactive Protein-albumin-lymphocyte Index For Patients With Recurrent οr Metastatic Head and Neck Squamous Cell Carcinoma Treated With Nivolumab.\",\"authors\":\"Fumihiko Sato, Takeharu Ono, Akira Hiraki, Tsunehiro Oka, Toshiyuki Mitsuhashi, Masayasu Naito, Mioko Fukahori, Shintaro Sueyoshi, Itaru Mizobe, Masahiro Seki, Kiminobu Sato, Toshihiko Kawaguchi, Hisaichiro Tanaka, Takashi Kurita, Shun-Ichi Chitose, Hirohito Umeno\",\"doi\":\"10.21873/anticanres.17757\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background/aim: </strong>Systemic inflammation, immunity, and nutrition-based prognostic indices (SIINBPIs) have been associated with cancer prognosis. This study evaluated their prognostic relevance in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) treated with nivolumab.</p><p><strong>Patients and methods: </strong>We retrospectively analyzed 103 R/M HNSCC patients who received nivolumab. Pretreatment blood tests were used to calculate SIINBPIs including the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), lymphocyte-to-monocyte ratio (LMR), high-sensitivity modified Glasgow Prognostic Score (HS-mGPS), and the C-reactive protein-albumin-lymphocyte (CALLY) index.</p><p><strong>Results: </strong>The CALLY index and performance status were identified as independent prognostic factors for overall survival (OS). Patients with a high CALLY index had better performance status and were more likely to receive subsequent chemotherapy. The CALLY index showed superior prognostic performance over other SIINBPIs.</p><p><strong>Conclusion: </strong>The CALLY index may serve as a useful and independent prognostic biomarker for R/M HNSCC patients undergoing nivolumab therapy, reflecting systemic status and predicting treatment outcomes.</p>\",\"PeriodicalId\":8072,\"journal\":{\"name\":\"Anticancer research\",\"volume\":\"45 9\",\"pages\":\"3993-4004\"},\"PeriodicalIF\":1.7000,\"publicationDate\":\"2025-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Anticancer research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.21873/anticanres.17757\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anticancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21873/anticanres.17757","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
Prognostic Value of the C-Reactive Protein-albumin-lymphocyte Index For Patients With Recurrent οr Metastatic Head and Neck Squamous Cell Carcinoma Treated With Nivolumab.
Background/aim: Systemic inflammation, immunity, and nutrition-based prognostic indices (SIINBPIs) have been associated with cancer prognosis. This study evaluated their prognostic relevance in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) treated with nivolumab.
Patients and methods: We retrospectively analyzed 103 R/M HNSCC patients who received nivolumab. Pretreatment blood tests were used to calculate SIINBPIs including the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), lymphocyte-to-monocyte ratio (LMR), high-sensitivity modified Glasgow Prognostic Score (HS-mGPS), and the C-reactive protein-albumin-lymphocyte (CALLY) index.
Results: The CALLY index and performance status were identified as independent prognostic factors for overall survival (OS). Patients with a high CALLY index had better performance status and were more likely to receive subsequent chemotherapy. The CALLY index showed superior prognostic performance over other SIINBPIs.
Conclusion: The CALLY index may serve as a useful and independent prognostic biomarker for R/M HNSCC patients undergoing nivolumab therapy, reflecting systemic status and predicting treatment outcomes.
期刊介绍：
ANTICANCER RESEARCH is an independent international peer-reviewed journal devoted to the rapid publication of high quality original articles and reviews on all aspects of experimental and clinical oncology. Prompt evaluation of all submitted articles in confidence and rapid publication within 1-2 months of acceptance are guaranteed.
ANTICANCER RESEARCH was established in 1981 and is published monthly (bimonthly until the end of 2008). Each annual volume contains twelve issues and index. Each issue may be divided into three parts (A: Reviews, B: Experimental studies, and C: Clinical and Epidemiological studies).
Special issues, presenting the proceedings of meetings or groups of papers on topics of significant progress, will also be included in each volume. There is no limitation to the number of pages per issue.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
